Results 1 to 10 of about 9,558 (217)

Optimizing the patient journey: Insights from early implementation of long‐acting cabotegravir and rilpivirine in four urban Ryan White‐funded clinics in the United States [PDF]

Journal of the International AIDS Society
Introduction Long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) represents a breakthrough in HIV treatment. However, understanding how to optimize real‐world service delivery and user experiences among people with HIV (PWH) remains limited ...
Xavier A. Erguera, Mollie B. Smith, Priyasha Pareek, Alicia Dawdani, Kaylin V. Dance, Ryan S. Walker, Janet Grochowski, Jon Oskarsson, Matthew D. Hickey, Mallory O. Johnson, John Sauceda, Jose I. Gutierrez Jr., Elizabeth T. Montgomery, Jonathan A. Colasanti, Lauren F. Collins, Moira C. McNulty, Kimberly A. Koester, Katerina A. Christopoulos   +17 more
doaj   +3 more sources

Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART [PDF]

Brain Sciences, 2019
Objective: Occult central nervous system (CNS) symptoms not recognized by people living with HIV (PLWH) receiving efavirenz or their clinicians could occur and impact people’s quality of life.
Jaime H. Vera, Margherita Bracchi, Jasmini Alagaratnam, Julianne Lwanga, Julie Fox, Alan Winston, Marta Boffito, Mark Nelson   +7 more
doaj   +3 more sources

Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study [PDF]

Journal of the International AIDS Society
Introduction Cabotegravir + rilpivirine long‐acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV‐1 treatment in virologically suppressed (viral load [VL]
Ricky K. Hsu, Michael G. Sension, Jennifer S. Fusco, Laurence Brunet, Quateka Cochran, Brooke Levis, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Michael B. Wohlfeiler, Gregory P. Fusco   +10 more
doaj   +2 more sources

Impact of Switching from Oral to Long-Acting Injectable Cabotegravir and Rilpivirine on the Lipid Profile of HIV-Positive Patients [PDF]

Microorganisms
Long-acting cabotegravir and rilpivirine (LA-CAB/RPV) have been incorporated into the treatment of people living with HIV (PLWH), but evidence on their metabolic impact in real-world settings remains limited.
Marta Segura Díaz, Antonio Collado Romacho, Sergio Ferra Murcia   +2 more
doaj   +2 more sources

Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug

Journal of Infection and Public Health, 2021
Background: COVID-19 disease caused by SARS-CoV-2 is lacking efficient medication although certain medications are used to relief its symptoms. Objectives: We tested an FDA-approved antiviral medication namely rilpivirine to find a drug against SARS-CoV ...
Fuad Ameen, Estari Mamidala, Rakesh Davella, Shravan Vallala   +3 more
doaj   +1 more source

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling

Frontiers in Pharmacology, 2022
Tuberculosis remains the leading cause of death among people living with HIV. Rifapentine is increasingly used to treat active disease or prevent reactivation, in both cases given either as weekly or daily therapy.
Sandra Grañana-Castillo, Maiara Camotti Montanha, Rachel Bearon, Saye Khoo, Marco Siccardi   +4 more
doaj   +1 more source

Real-life efficacy and satisfaction of long-acting ART Cabotegravir-Rilpivirine in HIV-infected individuals [PDF]

Infectious Diseases and Tropical Medicine, 2023
OBJECTIVE: Switching from oral anti-retroviral therapy (ART) to intramuscular administration of Cabotegravir-Rilpivirine (CAB+RPV) has been observed to decrease the number of pills that patients need to take, enhance patient satisfaction, and promote ...
S. Spampinato, A. Saia, Y. Russotto, C. Micali, A. Marino, M. Ceccarelli, E. Venanzi Rullo, G. Pellicanò, G. Nunnari   +8 more
doaj   +1 more source

Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials

Frontiers in Pharmacology, 2021
Objectives: To investigate the safety and pharmacokinetic profiles of long-acting injectable pre-exposure prophylaxis (LAI PrEP), notably cabotegravir (CAB-LA) and rilpivirine (RPV-LA), for the prevention of human immunodeficiency virus-1 (HIV-1 ...
Gilbert Lazarus, Vincent Kharisma Wangsaputra, Christianto, Melva Louisa, Vivian Soetikno, Raph L. Hamers, Raph L. Hamers, Raph L. Hamers   +7 more
doaj   +1 more source

Real-Time and Wireless Assessment of Adherence to Antiretroviral Therapy With Co-Encapsulated Ingestion Sensor in HIV-Infected Patients: A Pilot Study. [PDF]

, 2020
Adherence with antiretroviral therapy is important for preventing disease progression and HIV transmission. The co-encapsulated pill sensor system sends a signal through a cutaneous patch and allows real-time monitoring of pill ingestion. A 16-week pilot
Corado, Katya, Daar, Eric S, Dao, John, Fletcher, Courtney V, Guerrero, Mario, Liu, Honghu, Rosen, Marc I, Shen, Jie, Siqueiros, Lisa, Wang, Yan, Xiong, Di, Young, Todd   +11 more
core   +1 more source

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland

Pharmaceutics, 2022
SHCS#879 is an ongoing Switzerland-wide multicenter observational study conducted within the Swiss HIV Cohort Study (SHCS) for the prospective follow-up of people living with HIV (PLWH) receiving long-acting injectable cabotegravir-rilpivirine (LAI-CAB ...
Paul Thoueille, Susana Alves Saldanha, Fabian Schaller, Aline Munting, Matthias Cavassini, Dominique Braun, Huldrych F. Günthard, Katharina Kusejko, Bernard Surial, Hansjakob Furrer, Andri Rauch, Pilar Ustero, Alexandra Calmy, Marcel Stoeckle, Manuel Battegay, Catia Marzolini, Pascal Andre, Monia Guidi, Thierry Buclin, Laurent A. Decosterd, on behalf of the Swiss HIV Cohort Study   +20 more
doaj   +1 more source